Login to Your Account

ALK-aline battery: Pfizer trounced by phase III

By Randy Osborne
Staff Writer

Tuesday, June 6, 2017

CHICAGO – In what ASCO expert John Heymach described as a "watershed moment" for people with ALK-positive NSCLC, phase III findings showed that the Alecensa stopped tumor growth for a median of 15 months longer and caused fewer side effects.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription